http://orcid.org/0000-0003-0301-8145
Figures
Abstract
Dengue fever is known to be one of the most common arthropod-borne viral infectious diseases of public health importance. The disease is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, Southeast Asia and the Western Pacific with an estimated two fifths of the world's population being at risk. The notable endemic viral hemorrhagic fevers (VHFs) found in West Africa, including yellow fever, Lassa fever, Rift Valley fever, dengue fever and until recently Ebola have been responsible for most outbreaks with fatal consequences. These VHFs usually produce unclear acute febrile illness, especially in the acute phase of infection. In this study we detected the presence of 2 different serotypes (DENV-2 and DENV-3) of Dengue virus in 4 sera of 150 patients clinically suspected of Ebola virus disease during the Ebola Virus Disease (EVD) outbreak in West Africa with the use of serological and molecular test assays. Sequence data was successfully generated for DENV-3 and phylogenetic analysis of the envelope gene showed that the DENV-3 sequences had close homology with DENV-3 sequences from Senegal and India. This study documents molecular evidence of an indigenous Dengue fever viral infection in Ghana and therefore necessitates the need to have an efficient surveillance system to rapidly detect and control the dissemination of the different serotypes in the population which has the potential to cause outbreaks of dengue hemorrhagic fevers.
Citation: Bonney JHK, Hayashi T, Dadzie S, Agbosu E, Pratt D, Nyarko S, et al. (2018) Molecular detection of dengue virus in patients suspected of Ebola virus disease in Ghana. PLoS ONE 13(12): e0208907. https://doi.org/10.1371/journal.pone.0208907
Editor: Pierre Roques, CEA, FRANCE
Received: May 25, 2018; Accepted: November 26, 2018; Published: December 19, 2018
Copyright: © 2018 Bonney et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript. However, sequence data files for the three positive samples (EV-042, EV-050 and EV-073 for the gene target, capsid pre-membrane region) and two of the same samples (EV-042 and EV-073 for the gene target, non-structural 5 region) are available on the DNA Data Bank of Japan (DDBJ) and assigned the accession numbers LC379220 - LC379224.
Funding: This research work was supported by funds from the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) of the Japan Agency for Medical Research and Development (AMED) to NO and by the Government of Ghana through the financial support from the University of Ghana Research Fund to JH and KB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interest exists.
Introduction
Viral hemorrhagic fevers (VHFs), which refer to a group of illnesses that are caused by viruses within a distinct group of families, are well known for their characteristic overall vascular system damage and the impairment of the body’s ability to regulate itself [1]. Symptoms presented by VHF-related illnesses are often accompanied by hemorrhage which in itself is rarely life-threatening [1]. While some types of hemorrhagic fever viruses cause relatively mild illness, many of these viruses cause severe fatal disease. The occurrence of outbreaks caused by these viruses cannot be certainly projected However, in recent times, the world has come to terms with the devastating impact of mortality and morbidity unleashed by two viral agents within these distinct viral groups–Dengue virus and Ebola virus. While the mortality rate of the latter is known to be a little over 90% [2] in some instances, it is rather the morbidity rate in the former that causes extensive concern as the World Health Organization (WHO) indicated a 30-fold increase in cases since 1960 [3].
DF which is considered the most important Aedes mosquito-borne viral disease to infect humans is caused by one of four closely related serotypes of Dengue virus (DENV) [4]. The four serotypes, DENV serotypes 1–4, have caused large urban outbreaks, particularly once the co-circulation of different serotypes is observed or when a new serotype is presented [5–7]. The virus belongs to the genus Flavivirus within the Flaviviridae family [8]. It is endemic and known as a common illness throughout Southeast Asia and much of the Americas [8]. A study that used a cartographic approach provided an annual global estimate of 390 million DENV infections of which 67 to 136 million showed at any level of disease severity [9]. In this same study 70% of the global estimated infections were predicted to have occurred in Asia and 16% in Africa [9,10]. It was however noted with interest the large estimated burden of Dengue in Africa from this study as it was not until recently that the often-recognized disease outside Africa has assumed higher levels of risk in Africa [9,10].
The widespread epidemic of Ebola virus disease (EVD) in three West African countries, Guinea, Sierra Leone and Liberia, between 2013 and 2015 caused significant mortality, with reported case fatality rates of up to 72% [11] and specifically 57–59% among hospitalized patients [11]. Many West African countries including Ghana that are near to these three most affected countries were deemed at high risk of EVD importation. As a response to the outbreak in these neighboring countries, a national surveillance system was set up in Ghana as part of an EVD preparedness and response plan to detect and rapidly respond to cases and rumors of cases. Clinical specimens of serum/plasma from patients suspected of EVD from health facilities across the country were submitted to the Noguchi Memorial Institute for Medical Research (NMIMR), which was designated for laboratory investigation of these suspected cases.
To establish a definitive diagnosis for these suspected cases of EVD, a testing algorithm that involved investigating for the other known endemic VHFs in the sub-region was adopted. Thus, laboratory investigations were not only performed for Ebola and Marburg but the other endemic hemorrhagic fever viruses including Yellow fever, Lassa fever West Nile and DF. While a definitive viral diagnosis could not be established for the majority of the suspected cases, four were found to be positive for dengue virus with our testing algorithm. The import of this approach was reinforced when analysis of the case investigation forms that accompanied these suspected specimens suggested only 10% met the WHO standard case definition for an EVD [12]. From the foregoing, we sought to detect viral agents of hemorrhagic fevers likely to be endemic in the country from the suspected clinical specimens submitted for laboratory investigation of EVD. We intend to present the molecular indication of a native Dengue viral infection in Ghana.
Materials and methods
Clinical specimens
The clinical specimens of sera and plasma used in this study were archived specimens stored at Noguchi Memorial Institute for Medical Research (NMIMR). These samples had been collected between 2014 and 2016, during the West African EVD outbreak. Eligible patients were examined by trained health staff and diagnosed on suspicion of EVD illness based on the routine surveillance case definition of the standard WHO case definitions for Ebola and Marburg virus diseases [12]. During that period, they were tested for EVD and other VHFs including Marburg, Lassa fever, yellow fever and West Nile by reverse transcription polymerase chain reaction (RT-PCR). Residual specimens were stored at -80°C. Thus, the batch of specimens used in this work had previously been tested for EVD, Marburg, Lassa fever and yellow fever but were yet to be tested for other flaviviruses.
Ethical approval was obtained from the Noguchi Memorial Institute for Medical Research Institutional Review Board (NMIMR-IRB) and the Ghana Health Service for this research work (study number: #033/15-16). All analyzed patients’ clinical specimens used in this study were anonymized prior to access by the authors.
Serological assays
The 150 residual clinical specimens were individually tested with serological assays for the presence of antibodies to DENV. Test assays were performed in a 96-well ELISA format using commercially available kit and test procedure followed in accordance with manufacturer’s instructions: Human Anti-DENV IgG/IgM ELISA kit (Abcam, Cambridge, UK). Anti-DENV IgM positives were tested with a lateral flow immunochromatographic strip (Dengue NS1 Ag STRIP; Bio-Rad, Marnes-la-Coquette, France).
Nucleic acid extraction and purification
Viral RNA was extracted from 140 μL of clinical specimens that were anti-DENV IgM positive with the QIAmp viral RNA kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The extracted and purified nucleic acid was eluted from the spin columns with 60 μL of RNase/DNase-free elution buffer provided with the kit.
Nucleic acid amplification assays
To amplify the nucleic acid and detect the genomic sequence of interest, several amplification assays were deployed. An initial test run was carried out with a TaqMan-based real time reverse transcription-polymerase chain reaction (rRT-PCR) assay developed by Johnson et al. [13] to detect and type the four DENV serotypes. In a 25μl reaction mixtures with the Applied Biosystems 7300 RT-PCR system (Life Technologies, Grand Island, NY, USA), volumes each of 5μl of extracted and purified RNA from the clinical sera or plasma were combined with 10 pmol each of Dengue serotype specific primer and probe sets and targets. Each reaction mixture contained a single Dengue serotype primer pair and probe–making four separate reactions for the isolated and purified RNAs for each clinical specimen. The reagent master mix was prepared according to the number of reactions required for each test run using the AgPath-ID One-Step RT-PCR kit (#AM1005, Thermo Fisher Scientific, NY, USA). Then a final addition of 5μl of individual RNA to each appropriately labeled well. Included in each test run were ‘no RNA’ or nuclease-free water reagent and Dengue positive RNA control. A presumptive positive for Dengue serotype specific virus was considered for a clinical specimen when the controls met stated requirements and the growth curves crossed the threshold line within 40 cycles with the inverse true for negatively considered clinical specimens for Dengue serotype specific virus.
Conventional RT-PCR
In all, four conventional RT-PCR assays were performed and, in each test, run a volume of 25 μl with 5 μl nucleic acid extract was used as a template. The reagents, cycle numbers, primer sequences, target regions and amplicon lengths are shown in Table 1. The four conventional RT-PCR assays were performed using the Aeris G-96 well PCR system (Esco Micro Pte Ltd, Singapore). The amplification products were electrophoresed on a 2% Agarose gel (peqlab Biotechnologie, Erlangen, Germany), stained with Ethidium bromide, and viewed under UV light.
Sequencing and phylogenetic analysis
The conventional RT-PCR products were sequenced and were assembled using the DNASTAR’s Lasergene sequence analysis software with base calling proofread by graphic examination of the electropherograms. Phylogenetic trees were constructed based on 511 nucleotides of the capsid (pre-membrane) and the 266 nucleotides of the non-structural protein target genomic regions target genes and the analysis included the amplified samples from the conventional RT-PCR as well as GenBank reference sequences of 34 and 37 respectively (Table 2). The reference sequences were selected from representatives of the four DENV serotypes as well as closely related sequences to the query. Phylogenies were inferred by the maximum likelihood method and conducted in MEGA 7 [14]. It was drawn to scale, with branch lengths in the same units as those of the evolutionary distances used.
Results
ELISA and NS1 serological detection
The number of archived clinical specimens tested was from 150 patients and collected between the years 2014–2016 from all over the country (Fig 1). Anti-DENV IgM was detected in 32 samples while ant-DENV IgG was detected in 85 samples. Of the 32 anti-DENV IgM positives tested for NS1 Ag, 4 were detected as positive (IDs 29, 42, 50, 73), Table 3, Fig 2.
Map shows the different parts of the country where samples were collected. The symbol star shows where the four DENV positive samples were taken.
Immunochromatographic assay for DENV NS1Ag test for real time RT-PCR positive samples (29, 42, 50 and 73). Two samples (22 and 127) that were negative by real time RT-PCR were included for validation. a. Arrowhead: positive band; b. * indicates the four patient samples found to be positive.
PCR assays detection
All 32 patients’ clinical specimens that were found positive by ELISA for anti-DENV IgM antibodies were analyzed by several PCR assays. Using the TaqMan-based rRT-PCR assay, viral RNA was detected in 4 out of the 32 DENV IgM positive samples. They were characterized as 1 DENV-2 (sample ID 29) and 3 DENV-3 (sample IDs 42, 50 and 73) serotypes. Clear DNA fragments of expected sizes were observed for all but sample 29 when the conventional RT-PCR assays were performed on the 4 positive samples (Fig 3).
Gel images after amplification using the following primer set: a) FU1 and cFD2- expected size 266bp b) FU2 and cFD3 –expected size 845bp c) DUC and DUS–expected size 511bp d) NS5F1 and NS5R –expected size 917bp NC–Negative control PC–Positive control M–molecular ladder.
Sequence and phylogenetic analysis
To determine the genotypes and evolution of the viruses present in the positive patients’ samples, the amplicons from the conventional RT-PCR run were sequenced and subjected to phylogenetic analysis. The parsimony analysis by maximum likelihood method [15] and MEGA 7 [1] included the three amplified patient’s samples (42, 50 and 73), as well as GenBank reference sequences. In both phylogenetic trees, the patient’s samples were closely related to each other and clustered within DENV serotype 3 and in close homology with sequences from Senegal (KU509282) and India (FJ544564 and KU216208) (Fig 4A and 4B).
Phylogenetic trees were drawn using the maximum likelihood method a. Using DUC/DUS sequences b. Using FU1/cFD2 sequences.
Demographics and clinical details
Of the 4 patients in whom DENV RNA was detected, 2 were males and 2 were females with the age range of 30 to 56years old. Three (IDs 29, 50 and 73) are Ghanaian indigenes residing in the southern part of Ghana (Accra and Kasoa) and one (ID 42) being a Burkinabe who sought medical attention across the border between the two countries in Bawku, a town in the North Eastern part of Ghana. From the clinical characteristics, fever (temperature above 38°C) and muscle/joint pains were the most commonly seen in all patients on presentation. Other observed clinical features included headache, confused or disoriented seizures and unexplained bleeding from the gums and nose (Table 4).
Discussion
A decade ago, the global distribution of the risk of DENV infection and its public health burden were poorly known with little information from Africa [5]. However, recent studies and outbreaks in Burkina Faso and Senegal [16–19] as well as the forces of urbanization and globalization have facilitated the emergence of Dengue and other Arboviruses [5] and increased their surveillance and diagnostic activities in sub-Saharan Africa. This study has therefore added to the body of knowledge and scientific data, the molecular evidence of the presence of the West African commonly found DENV-2 and DENV-3 serotypes in Ghana. This finding supports the co-circulation and concurrent infections by multiple DENV serotypes which has become a frequent occurrence in endemic countries [20,21].
Dengue serotype 2 has been dominant in West Africa [22] and this was given credence with the recent outbreaks in Burkina Faso and Senegal [17]. In an earlier hospital-based study conducted in a peri-urban area in Ghana, we sought to identify pathogens that cause febrile illnesses among children. Of the 700 enrolled, 2 were found to be acutely infected with DENV-2 when viral RNA was detected using molecular tools [23]. The dominance of Dengue 2 may be attributed to the prevalence of the strain of the transmissible vector in the sub-region. DENV serotypes and strains within the serotypes are known to vary in their ability to infect and disseminate in mosquitoes [24,25]. Dengue serotype 2 strains have been demonstrated to be better adapted and tend to infect the highly domesticated Ae. aegypti more efficiently [26]. It is thus considered the principal vector for DENV in urban areas whereas the species Ae. albopictus is recognized as an important vector in some rural areas [27].
The additional detection of DENV-3 and its relative proportion against DENV-2 in our study makes it a dual or multiple circulation of serotypes. This suggests possibility of concurrent serotype infections within the population. With the documented evidence that concurrent circulation by multiple Dengue serotypes influences clinical expression and accounts for the emergence of Dengue Hemorrhagic fevers (DHFs) [24], our finding presents a cause for public health concern in a country where hitherto hospital-based clinical and laboratory-based virologic surveillance system for DENV infection is inadequate. Since 1982 when the first case of concurrent infections with 2 DENV serotypes was reported in Puerto Rico [28], there have been documented reports of several concurrent infections in other countries [29, 30] and usually, though not in all cases, concurrent infections occur during epidemics or outbreaks. Our study finding of the co-circulating serotypes which also suggests hyperendemicity but without any apparent clinical or sub-clinical manifestation of DF or DHF may be partly due to the lack of hospital and laboratory-based surveillance at the time. It could also in part be attributed to the events at the time (during the peak of the EVD epidemic in West Africa) when the patients presented to the health facility were paid more attention because of the heightened alert for EVD suspected cases. Nevertheless, an absence of DHF notwithstanding hyperendemic co-circulating DENV transmission was also observed in a study in Haiti [31].
The rare clinical features observed with two of the four patients who tested positive for DF were in confused or disoriented state and unconsciousness. Although these features are usually not described to define a case of DF/DHF however, our observations are consistent with studies that have described unusual neurological manifestations of Dengue infection, including non-specific symptoms to encephalitis and, rarely, Guillain-Barré syndrome [32, 33]. Additionally, DENV-2 and DENV-3 are recurrently described as the cause of neurological sequelae [32]. It was worth noting that all the 4 positive patients had high grade fever and muscle/joint pains as main symptomatology in conformity with the WHO case definition [34] for DF. Further to that, 2 of the patients (IDs 50 and 73) had evidence of hemorrhagic manifestations, suggesting cases of DHF [33].
In our study analysis, we performed sequence phylogeny to confirm and establish the serotypes of the positive patient’s samples as documented reports in the sub-region on the circulation of different DENV serotypes are poor. Few publications however provide information on outbreaks and serological surveillance studies and reports that documented DENV infection in travellers. The results confirmed our serotypes as closely related to each other and clustered within DENV serotype 3 and in close homology with sequences from Senegal (KU509282) and India (FJ544564 and KU216208). Nonetheless, DENV-2 has been the main serotype reported to be circulating in West Africa [35] since the case of DENV was detected in Nigeria in 1964 [36]. In the West African countries of Côte d’Ivoire, Burkina Faso and Guinea, DENV-2 was detected from sylvatic cycles [37–39] and more closely in 2005, DENV-2 was identified in a traveller who returned from Ghana [40]. Despite this, DENV-3 has been detected severally in Africa [41, 42] with an instance where analysis suggested the importation of the virus from the Indian sub-continent [43]. Again, in our neighbouring country Côte d’Ivoire, DENV-3 was documented to have been co-circulating with Yellow fever [44]. These reports corroborate our finding of DENV-3 circulation in Ghana which has been noted to be consistent with evidence that this serotype is spreading in the sub-region [45].
In conclusion, we report the detection of 2 different serotypes of DENV circulating among patients suspected of EVD in Ghana. This makes for a public health interest on local DF burden and epidemiology and offers the platform to improve surveillance, laboratory testing capacity and clinical alertness in the health delivery system within the country and the sub-region.
Acknowledgments
Our gratitude goes to the Ghana Health Service for the permission granted for the use of the clinical specimens, the health staff and facilities across the country who and where these specimens were collected and submitted for testing and the VHF team at the Virology Department at Noguchi Memorial Institute for Medical Research.
References
- 1.
Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB). January 29, 2015. Available from: https://www.cdc.gov/vhf/index.html
- 2.
World Health Organization. Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation. Geneva (CH): World Health Organization; 2014. p. 12. Report no.: INTERIM version 1.2.
- 3.
Global alert and response–impact of dengue. Accessed July 27, 20115. Available from: http://www.who.int/csr/disease/dengue/impact/en/
- 4. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. N. Engl. J. Med. 366, 1423–1432 (2012). pmid:22494122
- 5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013 Apr 25; 496(7446): 504–507. pmid:23563266
- 6. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. Journal of Clinical Microbiology. 1992; vol. 30, no. 3, pp. 545–551. pmid:1372617
- 7. Gubler DJ. Epidemic dengue: dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002; 10:100–103. pmid:11827812
- 8.
Alan L, Schmal J, McClain D. Alphaviruses (Togaviridae) and Flaviviruses (Flaviviridae). Book chap., 54, Medical Microbiology. 4th edition. Baron S, editor. Galveston (TX): University of Texas Medical Branch at Galveston; 1996.
- 9. Natasha E, Murray A, Quam MB. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013; 5: 299–309. pmid:23990732
- 10. Terzian ACB, Mondini A, Vieira R. Detection of Saint Louis Encephalitis Virus in Dengue-Suspected cases during a Dengue 3 outbreak. Vector Borne and Zoonotic Diseases, 2011; Vol. 11, Number 3.
- 11. Roca A, Afolabi MO, Saidu Y, Kampmann B. Ebola: A holistic approach is required to achieve effective management and control. J Allergy Clin Immunol. 2015 Apr; 135(4): 856–867. pmid:25843598
- 12.
World health Organization: Accessed May 2016. Available from: http://www.who.int/csr/resources/publications/ebola/case-definition/en/
- 13. Johnson BW, Russell BJ, Lanciotti RS. Serotype-Specific Detection of Dengue Viruses in a Fourplex Real-Time Reverse Transcriptase PCR Assay. Journal of Clinical Microbiology. 2005;43(10):4977–4983. pmid:16207951
- 14. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0. 2015. Molecular Biology and Evolution
- 15. Saitou N, Nei M. The Neighbor-Joining Method-a New Method for Reconstructing Phylogenetic Trees. Mol Biol Evol 4: 406–425. pmid:3447015
- 16. Stoler J, Delimini RK, Bonney JHK, Oduro AR, Owusu-Agyei S, Fobil JN, et al. Evidence of Recent Dengue Exposure among Malaria Parasite-Positive Children in Three Urban Centers in Ghana; Am. J. Trop. Med. Hyg., 92(3), 2015, pp. 497–500 pmid:25582693
- 17.
Weekly Bulletin on Outbreak and other Emergencies: Week 44: 28 October–03 November, World Health Organization (WHO) Regional office for Africa, WHO Health Emergencies Program
- 18. Stoler J, al Dashtib R, Anto F. Deconstructing “malaria”: West Africa as the next front for dengue fever surveillance and control, Acta Tropica. 2014;134, 58–65. pmid:24613157
- 19. WHO: Dengue/dengue hemorrhagic fever. Weekly Epidemiol Rec 2000, 75:193–196.
- 20. Wilder-Smith A, Yoksan S, Earnest A. Serological evidence for the co-circulation of multiple dengue virus serotypes in Singapore; Epidemiol. Infect. 2005; 133, 667–671. f 2005 Cambridge University Press pmid:16050512
- 21. Loron˜ O-Pino MA, Cropp CB, Farfa JA, Vorndam V. Common Occurrence of Concurrent Infections by Multiple Dengue Virus Serotypes; Am. J. Trop. Med. Hyg., 61(5), 1999, pp. 725–730 Copyright q 1999 by The American Society of Tropical Medicine and Hygiene pmid:10586902
- 22. Cordellier R, Bouchite B, Roche JC, Monteny N, Diaco B, Akoliba P. Circulation silvatique du virus dengue 2 en 1980, dans les savannes sub-soudaniennes du Cote d’Ivoire. Cah ORSTOM Ser Entomol Med Parasitol 1983; 21:165–179
- 23. Amoako N, Duodu S, Dennis FE, Bonney JHK, Asante KP, Ameh J, et al. Dengue virus serotype 2 detected in febrile children in a peri-urban area of Accra, Ghana using a multiple-pathogen assay. Emerg Infect Dis. 2018;24(8):1544–1547. pmid:30015610
- 24. Gubler DJ, Nalim S, Tan R, Saipan H, Sulianti Saroso J. Variation in susceptibility to oral infection with dengue viruses among geographic strains of Aedes aegypti. Am J Trop Med Hyg 1979; 28:1045–1052. [PubMed: pmid:507282]
- 25. Rosen L, Roseboom LE, Gubler DJ, Lien JC, Chaniotis BN. Comparative susceptibility of mosquito species and strains to oral and parenteral infection with dengue and Japanese encephalitis viruses. Am J Trop Med Hyg 1985; 34:603–615. [PubMed: pmid:2860816]
- 26. Armstrong PM, Rico-Hesse R. Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus. Vector Borne Zoonotic Dis 2001; 1:159–168. [PubMed: pmid:12680353
- 27. Higa Y. Dengue Vectors and their Spatial Distribution. Tropical Medicine and Health. 2011;39(4 Suppl):17–27. pmid:22500133
- 28. De Carvalho Araujo FM, Nogueira RMR, De Araujo JMV, Ramalho ILC, De Sa Roriz MLF, De Melo MEL, Coelho ICB. Concurrent infection with dengue virus type-2 and DENV-3 in a patient from Ceara, Brazil. Memorias do Instituto Oswaldo Cruz 2006; 101:925–8. pmid:17293990
- 29. Laille M, Deubel V, Sinte-Marie FF. Demonstration of concurrent dengue 1 and dengue 3 infection in six patients by the polymerase chain reaction. Journal of Medical Virology 1991; 34:51–4. pmid:1885943
- 30. Maneekarn N, Morita K, Tanaka M, Igarashi A, Usawattanakul W, Sirisanthana V, Innis BL, Sittisombut N, Nisalak A, Nimmanitya S. Applications of polymerase chain reaction for identification of dengue viruses isolated from patient sera. Microbiology and Immunology 1993; 37:41–7. pmid:8474356
- 31. Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, Sun W, et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001; 65: 180–183. pmid:11561700
- 32. Soares CN, Faria LC, Peralta JM, de Freitas MR, Puccioni Sohler M. Dengue infection: neurological manifestations and cerebrospinal fluid (CSF) analysis. Journal of the Neurological Sciences. 2006; 249, 19–24. pmid:16870213
- 33. Lum LC, Lam SK, Choy YS, George R, Harun F. Dengue encephalitis: a true entity? Am Trop Med Hyg 1996;54(3):256–9.
- 34.
Centers for Disease Control and Prevention (US CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD). Accessed March 2, 2018. Available from: https://www.cdc.gov/dengue/clinicallab/casedef.html
- 35.
Sang RC. Dengue in Africa. Nairobi, Kenya, Arbovirology/Viral Haemorrhagic Fever Laboratory, Centre for Virus Research, Kenya Medical Research Institute, 2007. Accessed October 21, 2009. Available from: http://www.tropika.net/review/061001-Dengue_in_Africa/article.pdf.
- 36. Carey DE, Causey OR, Reddy S, Cooke AR. Dengue viruses from febrile patients in Nigeria,1964–68. Lancet. 1971;1(7690):105–6. pmid:4099602
- 37. Vasilakis N, Holmes EC, Fokan EB, Faye O, Diallo M, Sall AA, et al. Evolutionary process among sylvatic dengue type 2 viruses. J. Virol. 2007;81(17):9591–5 pmid:17553878
- 38. Zeller HG, Traoré-Lamizana M, Monlun E, Hervy JP, Mondo M, Digoutte JP. Dengue-2 virus isolation from humans during an epizootic in southeastern Senegal in November 1990. Res Virol. 1992;143(2):101–2. pmid:1594790
- 39. Diallo M, Ba Y, Sall AA, Diop OM, Ndione JA, Mondo M, et al. Amplification of the sylvatic cycle of dengue virus type 2, Senegal, 1999–2000: Entomologic findings and epidemiologic considerations. Emerg Infect Dis. 2003;9(3):362–7. pmid:12643833
- 40. Huhtamo E, Uzcátegui N, Siikamäki H, Saarinen A, Piiparinen H, Vaheri A, et al. Molecular epidemiology of dengue virus strains from Finnish Travelers. Emerg Infect Dis. 2008;14(1):80–3. pmid:18258084
- 41. Gubler DJ, Sather GE, Kuno G, Cabral JR. Dengue 3 virus transmission in Africa. Am J Trop Med Hyg. 1986; 35:1280–4. pmid:3789276
- 42. Sharp TW, Wallace MR, Hayes CG, Sanchez JL, DeFraites RF, Arthur RR, et al. Dengue fever in US troops during Operation Restore Hope, Somalia, 1992–1993. Am J Trop Med Hyg. 1995; 53:89–94. pmid:7625541
- 43. Messer WB, Gubler DJ, Harris E, Sivananthan K, De Silva AM. Emergence and global spread of dengue serotype 3, Subtype III virus. Emerg Infec Dis. 2003; 9(7):800–9.
- 44.
Dengue in Africa: emergence of DENV-3 Cote d’Ivoire, 2008. [No authors listed]. WHO Wkly Epidemiol Rec.2009; 84(11–12):85–8. Article in English, French.
- 45. Franco L, Di Caro A, Carletti F, Vapalahti O, Renaudat C, Zeller H, Tenorio A. Recent expansion of dengue virus serotype 3 in West Africa. Eurosurveillance. 2010; Volume 15, Issue 7
- 46.
Kekenhi project. Available from: https://kaken.nii.ac.jp/en/file/KAKENHI-PROJECT-25670267/25670267seika.pdf
- 47. Kuno G, Chang G-JJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the Genus Flavivirus. J Virol 1998;72(1);73–83 pmid:9420202